Clinical neuropathology practice news 2-2012: BRAF V600E testing

Area of Science:

• Oncology
• Molecular Pathology
• Genetics

Background:

• Activating BRAF (v-RAF murine sarcoma viral oncogene homologue B1) mutations, particularly V600E, are prevalent in various human cancers.
• BRAF inhibitors demonstrate significant efficacy in treating metastatic melanoma with BRAF V600E mutations, including those with brain involvement.

Purpose of the Study:

• To highlight the clinical significance of BRAF V600E mutation testing in neuropathology.
• To evaluate the utility of BRAF testing in managing melanoma brain metastases and diagnosing primary brain tumors.

Main Methods:

• Utilized DNA-based methods and immunohistochemistry with a V600E mutation-specific antibody for BRAF mutation status determination.
• Reviewed clinical data on BRAF V600E mutations in melanoma metastases and primary brain tumors like anaplastic pleomorphic xanthoastrocytoma and glioblastoma.

Main Results:

• BRAF V600E testing is clinically indicated for melanoma brain metastases to identify patients eligible for BRAF inhibitor therapy.
• BRAF V600E mutations are found in approximately 65% of anaplastic pleomorphic xanthoastrocytomas but less than 5% of glioblastomas, aiding differential diagnosis.

Conclusions:

• BRAF V600E testing currently holds significant predictive value for melanoma brain metastases treatment.
• Future studies may expand the clinical relevance of BRAF mutation status determination for primary brain tumors, including glioblastoma.